Advertisement

Should Liquid Biopsies Be Considered in Treatment Decisions?

  • Barina Andrea
  • Maretto Isacco
  • Pucciarelli Salvatore
Chapter

Abstract

Biopsies have a central role in disease management, particularly in cancer patients. They allow clinicians to diagnose, determine treatment and evaluate prognosis. Other than specifying the histological nature of the disease, tissue biopsies are used to determine the genetic features of the tumour, which can be used to treat patients with drugs that are tailored to the genetic make-up of their tumour and to give predictive and prognostic information.

References

  1. 1.
    Gerlinger M et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequecing. N Engl J Med 366:883–892CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Crowley E et al (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10:472–484CrossRefPubMedGoogle Scholar
  3. 3.
    Bettegowda C et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224CrossRefGoogle Scholar
  4. 4.
    Thierry AR et al (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20:430–435CrossRefPubMedGoogle Scholar
  5. 5.
    Heitzer E et al (2013) Circulating tumor cells and DNA as liquid biopsies. Genome Med 5:73CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chan KC et al (2013) Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number ab- errations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A 110:18761–18768CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chan KC et al (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single- nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59:211–224CrossRefPubMedGoogle Scholar
  8. 8.
    Heitzer E et al (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 133:346–356CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Frattini M et al (2008) Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 26:170–181CrossRefGoogle Scholar
  10. 10.
    Diehl F et al (2008) Circulating mutant DNA to assess tumour dynamics. Nat Med 14:985–902CrossRefPubMedGoogle Scholar
  11. 11.
    Lecomte T et al (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548CrossRefPubMedGoogle Scholar
  12. 12.
    Bertorelle R et al (2013) Telomerase is an indipendent prognostic marker of overall survival in patients with colorectal cancer. Br J C 108:278–284CrossRefGoogle Scholar
  13. 13.
    Karapetis CS et al (2008) KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMedGoogle Scholar
  14. 14.
    Kuo YB et al (2014) Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta 433:284–289CrossRefPubMedGoogle Scholar
  15. 15.
    Diaz LA et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Pucciarelli S et al (2012) Telomerase-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol 19:3089–3096CrossRefPubMedGoogle Scholar
  17. 17.
    Agostini M et al (2011) Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol 18:2461–2468CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Barina Andrea
    • 1
  • Maretto Isacco
    • 1
  • Pucciarelli Salvatore
    • 1
  1. 1.Department of Surgical, Oncological and Gastroenterological SciencesUniversity of PadovaPadovaItaly

Personalised recommendations